Products & ServicesEvent: September 8, 2026
Sonas Pharma Emma Cheetham is building SNS-101 against the bar for orphan paediatric epilepsy.
Published
Signal category
Products & Services
Quote
“What I think that means practically: the companies that do well in this space won't be the ones with the loudest chemistry story. They'll be the ones who can make a rigorous, specific case for why their molecule is actually different from what's already approved”
— Chris Hayes|Sonas Pharma team
Company
Sonas Pharma
Innovative ECS medicines for the future.
- Industry
- Biotechnology Research
- Location
- Belfast, GB
- Company size
- 2 employees
Developing innovative ECS medicines to treat epilepsy and obesity.